Stephen Johnson1,2, Hideyuki Kano3,4,5, Andrew Faramand1,2, Matthew Pease1,2, Aya Nakamura1,2, Mohab Hassib1,2, David Spencer1,2, Nathaniel Sisterson1,2, Amir H Faraji1,2, Yoshio Arai6,2, Edward Monaco1,2, Ajay Niranjan1,2, John C Flickinger6,2, L Dade Lunsford1,2. 1. Departments of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA. 2. The Center for Image-Guided Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA. 3. Departments of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA. kanoh@upmc.edu. 4. The Center for Image-Guided Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA. kanoh@upmc.edu. 5. Neurological Surgery, University of Pittsburgh, UPMC Presbyterian, Suite B-400, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. kanoh@upmc.edu. 6. Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
Abstract
BACKGROUND: Stereotactic radiosurgery (SRS) has become a primary option for management for both newly diagnosed vestibular schwannomas (VS), as well as VS that enlarge after initial observation. METHODS: A retrospective review of our prospectively maintained data base found 871 patients who underwent Gamma knife® SRS as their initial (primary) management between 1987 and 2008. Follow-up ranged from 1-25 years (median = 5.2 years) Median tumor volume was 0.9 cc (0.02-36) and median margin dose was 13 Gy (12-25). RESULTS: Progression free survival (PFS) after SRS was 97% at 3 years, 95% at 5 years, and 94% at 10 years. Freedom from delayed surgical resection was found in 98.7% of patients. Smaller tumor volume was significantly associated with improved PFS. There were 326 patients with serviceable hearing (Gardner-Robertson 1 or 2) at the time of SRS with audiological follow-up of ≥ 1 year. Serviceable hearing preservation rates after SRS were 89.8% at 1 year, 76.9% at 3 years, 68.4% at 5 years, 62.5% at 7 years, and 51.4% at 10 years. Factors associated with improved serviceable hearing preservation included younger age, Gardner-Robertson grade 1 at SRS, and absence of subjective complaints of dysequilibrium or vertigo (vestibulopathy). Fifty-one patients (5.8%) developed trigeminal neuropathy. Fourteen (1.6%) developed a transient House-Brackmann grade 2 or 3 facial neuropathy. CONCLUSIONS: In this report with extended follow-up, primary SRS achieved tumor growth control in 94% of patients. Optimization of long- term cranial nerve outcomes remains an important achievement of this management strategy for VS.
BACKGROUND: Stereotactic radiosurgery (SRS) has become a primary option for management for both newly diagnosed vestibular schwannomas (VS), as well as VS that enlarge after initial observation. METHODS: A retrospective review of our prospectively maintained data base found 871 patients who underwent Gamma knife® SRS as their initial (primary) management between 1987 and 2008. Follow-up ranged from 1-25 years (median = 5.2 years) Median tumor volume was 0.9 cc (0.02-36) and median margin dose was 13 Gy (12-25). RESULTS: Progression free survival (PFS) after SRS was 97% at 3 years, 95% at 5 years, and 94% at 10 years. Freedom from delayed surgical resection was found in 98.7% of patients. Smaller tumor volume was significantly associated with improved PFS. There were 326 patients with serviceable hearing (Gardner-Robertson 1 or 2) at the time of SRS with audiological follow-up of ≥ 1 year. Serviceable hearing preservation rates after SRS were 89.8% at 1 year, 76.9% at 3 years, 68.4% at 5 years, 62.5% at 7 years, and 51.4% at 10 years. Factors associated with improved serviceable hearing preservation included younger age, Gardner-Robertson grade 1 at SRS, and absence of subjective complaints of dysequilibrium or vertigo (vestibulopathy). Fifty-one patients (5.8%) developed trigeminal neuropathy. Fourteen (1.6%) developed a transient House-Brackmann grade 2 or 3 facial neuropathy. CONCLUSIONS: In this report with extended follow-up, primary SRS achieved tumor growth control in 94% of patients. Optimization of long- term cranial nerve outcomes remains an important achievement of this management strategy for VS.
Authors: Hossein Mahboubi; Ronald Sahyouni; Omid Moshtaghi; Kent Tadokoro; Yaser Ghavami; Kasra Ziai; Harrison W Lin; Hamid R Djalilian Journal: Otolaryngol Head Neck Surg Date: 2017-04-25 Impact factor: 3.497
Authors: Berkcan Akpinar; Seyed H Mousavi; Michael M McDowell; Ajay Niranjan; Amir H Faraji; John C Flickinger; L Dade Lunsford Journal: Int J Radiat Oncol Biol Phys Date: 2016-01-19 Impact factor: 7.038
Authors: Daniel E Killeen; Anthony M Tolisano; Brandon Isaacson; J Walter Kutz; Samuel Barnett; Zabi Wardak; Jacob B Hunter Journal: J Neurol Surg B Skull Base Date: 2020-10-05
Authors: Torin P Thielhelm; Aida Nourbakhsh; Scott M Welford; Eric A Mellon; Olena Bracho; Michael E Ivan; Fred Telischi; Cristina Fernandez-Valle; Christine T Dinh Journal: Otolaryngol Head Neck Surg Date: 2022-03-01 Impact factor: 5.591
Authors: Sergio W Guadix; Alice J Tao; Anjile An; Michelle Demetres; Umberto Tosi; Swathi Chidambaram; Jonathan P S Knisely; Rohan Ramakrishna; Susan C Pannullo Journal: Neurooncol Pract Date: 2021-08-13
Authors: Umberto Tosi; Sergio Guadix; Anjile An; Drew Wright; Paul J Christos; Susan Pannullo; Andrew Brandmaier; Jonathan P S Knisely; Philip E Stieg; Rohan Ramakrishna Journal: Neurooncol Pract Date: 2021-02-01